Results 191 to 200 of about 677,625 (318)

Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review. [PDF]

Heart Fail Rev
Van Spall HGC, Vardeny O.
europepmc   +1 more source

The role of verbal suggestions in the placebo effect: introduction to a study design

reservedIntroduzione: L’effetto placebo è un fenomeno complesso che è determinato dall’interazione di componenti diverse, tra cui quella fisiologica, neurochimica e psicologica.
BONOTTO, AURORA
core  

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani, Braidon A. Lape, Anneliese M. Harp, Victoria Weisbrod, Lavinia Piazza   +4 more
wiley   +1 more source

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. [PDF]

Blood Adv
Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes J, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA.   +15 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Rethinking placebos [PDF]

Nature Medicine, 2014
openaire   +1 more source

Effects of Selective Sphingosine-1-Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four-Way Cross-Over Study in Healthy Volunteers. [PDF]

Eur J Pain
Bakker WA, Eijsvogel P, Klaassen ES, Kim J, Chen R, Demitrack MA, Dahan A, Niesters M, Hijma HJ, Groeneveld GJ.   +9 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Effects of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacological Effects of Orally Administered Tramadol: A Randomised Controlled Trial. [PDF]

Basic Clin Pharmacol Toxicol
Saarikoski T, Saari TI, Backman JT, Niemi M, Neuvonen PJ, Olkkola KT, Laine K.   +6 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source